A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

NCT05271682 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: FHND6091

Sponsor

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.